ERBB2 and breast cancer: Considering TILs as an important predictor of prognosis in BC patients (4, 14–16), we found that patients with higher TIL levels (>10%) in HER2-low-positive and HER2-nonamplified BC had a significant survival benefit compared with patients with lower levels of TILs (≤10%).